Agendia BV Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment

IRVINE, Calif. and AMSTERDAM--(BUSINESS WIRE)--In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use of conventional IHC-FISH pathology tests.

The prospective observational study of 426 patients was recently published online by the Annals of Surgical Oncology. It concludes that the BluePrint assay may be a better guide than IHC-FISH tests in making decisions about how to treat early-stage breast cancer before surgery.

Help employers find you! Check out all the jobs and post your resume.